ArticleScientific reports2026
Green NiO nanoparticle catalyzed synthesis of novel triazolopyrimidine derivatives with physicochemical characterization and computational evaluation for gout therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel series of triazolopyrimidine derivatives (5a-d and 6a-c) was synthesized via a green NiO nanoparticle-catalyzed protocol under mild conditions, affording the target compounds in good to excellent yields. The NiO nanoparticles exhibited high catalytic efficiency, attributed to their nanoscale features and porous structure, as confirmed by physicochemical characterization. Structural elucidation of the synthesized compounds was achieved using standard spectroscopic techniques. Computational studies, including density functional theory and molecular docking, were employed to evaluate the reactivity and potential multi-target activity of the compounds against key proteins involved in gout pathogenesis. The results revealed that selected derivatives exhibited favourable binding affinities toward multiple inflammatory targets, supported by stable protein-ligand interactions in molecular dynamics simulations. These findings suggest that the synthesized compounds may serve as potential multi-target candidates for gout therapy and warrant further biological investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.